
About us
Our story
Micrima Ltd was founded in 2005 as a spin-out from the University of Bristol, where radar technology originally developed for landmine detection was adapted for breast cancer imaging.
In the early 2000’s, Professor Ian Craddock and his team evolved their research into a PhD project, laying the foundations for a non-ionizing, radio-frequency imaging system with a mission to bring safer, more accessible breast imaging to women everywhere. A decade later, our first commercial system, MARIA™, gained CE approval and was used in clinical settings.
Listening to clinicians, patients, and the wider healthcare community, we recognised that the greatest need wasn’t only in diagnosis—it was in understanding breast tissue itself. So, we pivoted. Drawing on nearly 20 years of dedication, innovation, and clinical collaboration, we developed a new generation of technology: Mi~Scan® and Mi~Scan®+.
Mi~Scan® uses harmless radio waves to quickly measure breast tissue properties—without compression, discomfort, or radiation, and in almost any setting.
Mi~Scan®+ translates that data into breast density maps and risk profiles, integrating directly with existing breast cancer risk models to support personalised screening pathways.
Today, we are a diverse and passionate team of engineers, software developers, healthcare professionals, and innovators. We work closely with leading clinicians and clinics to validate our technology and bring its benefits to women worldwide.
Our mission is clear: to redefine breast cancer diagnostics by providing fast, personalised breast cancer risk and density scores for all women in any location.
Meet The Team
Learn more
-
Our Tech
Breast tissue analysis with radio frequency. Instant results in our custom software with breast cancer risk calculator integration.
-
Breast Density
Breast density can obscure cancer on a mammogram. Breast cancer risk increases as density increases. Learn more below.
-
Mi~Story
Numbers are important, but each story counts. Read about the experiences of women with breast cancer and dense breasts.